Case Report

Contiguous Xp11.4 Gene Deletion Leading to Ornithine Transcarbamylase Deficiency Detected by High-density Single-nucleotide Array

Mizuho Ono1, Junnosuke Tsuda2, Yoko Mouri2, Junichi Arai2, Tadao Arinami1, and Emiko Noguchi1

1Department of Medical Genetics, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Ibaraki, Japan
2Department of Neonatology, Mito Children’s Hospital, Ibaraki, Japan

Abstract. Ornithine transcarbamylase (OTC) is one of the enzymes involved in the urea cycle. OTC deficiency, which is caused by impaired synthesis of OTC in the liver, is the most common inherited disease of urea cycle disorders. In this paper, we describe the case of an OTC-deficient Japanese boy wherein an analysis based on high-density single-nucleotide polymorphisms (SNPs) revealed the absence of the entire OTC locus and nearby genes. We identified a deletion on Xp11.4; the size of the deletion fragment was approximately 1 Mb. The deleted region included genes encoding transmembrane 4 superfamily member 2 (TSPAN7), MID1 interacting protein 1 (MID1IP1) and part of the retinitis pigmentosa GTPase regulator (RPGR) in addition to OTC. The results of a high-density SNP assay and PCR confirmed that the mother of the patient was a carrier of the mutation. Previously, determination of breakpoints for large unknown deletions was timeconsuming and laborintensive. However, the use of the widely available DNA chip technology allows for rapid determination of deletion breakpoints; therefore, it will become a standard technique in study of patients with a large genomic deletion of contiguous genes for provision of comprehensive genetic counseling and initiation of clinical management.

Key words: OTC deficiency, high-density SNP assay, RPGR

Introduction

Ornithine transcarbamylase (OTC; OMIM 300461), a mitochondrial matrix enzyme, is one of the enzymes involved in the urea cycle; this enzyme catalyzes the biosynthesis of citrulline from ornithine and carbamyl phosphate. The human OTC gene is located on the short arm of the X chromosome (1), and OTC deficiency (OMIM 311250), which is caused by impaired synthesis of OTC in the liver, is the most commonly inherited disease of urea cycle disorders (2). The clinical signs and symptoms of this disease are caused by the toxic effects of hyperammonemia on the brain (3). Complete OTC deficiency in a male infant is usually lethal or results in severe brain damage (4). Heterozygous female carriers of this disorder may show great variation in the number of
enzyme-deficient hepatocytes, and hence, the clinical picture may vary from an asymptomatic carrier status to severe disease with hyperammonemic episodes and central nervous system damage (5).

Most of the disease-causing mutations in OTC deficiency are missense/nonsense mutations, and a recent study in which array comparative genomic hybridization (CGH) analysis was performed has shown that 15.7% of the DNA samples obtained from patients without disease-causing point mutations showed loss of a part or all of the OTC gene (6). There are some disease-causing genes located close to OTC, such as the dystrophin-encoding gene causing muscular dystrophy (7) and retinitis pigmentosa GTPase regulator (RPGR; OMIM 312610) causing retinitis pigmentosa (8); therefore, it is important to detect the deleted region in the genome of patients in order to determine the course of treatment and provide genetic counseling. In this paper, we describe the case of an OTC deficient-Japanese boy wherein high-density single-nucleotide polymorphism (SNP) analysis revealed the absence of the entire OTC locus and nearby genes.

**Patient Characteristics**

A Japanese male infant was delivered at full term via a cesarean section because of pregnancy toxemia. He was the first child in the family, and there was no family history of sudden infant death or inborn error of metabolism. He was well at birth and had a birth weight of 3,345 g, but developed tremors in both arms on day 1. He was admitted to the hospital for further evaluation on day 2. He developed tachypnea, and laboratory tests revealed hyperammonemia (733 µg/dl). He was kept in an incubator and treated with dialysis. His ammonia level elevated up to a maximum of 5,730 µg/dl but remained in the range of 200–300 µg/dl during treatment. The plasma levels of amino acids, which were determined using a blood sample collected on day 3, were as follows: glutamine, 3,739.3 nmol/ml (normal range, 422.1–703.8 nmol/ml); citrulline, trace amounts (normal range, 17.1–42.6 nmol/ml); ornithine, 172.4 nmol/ml (normal range, 31.3–104.7 nmol/ml); lysine, 573.0 nmol/ml (normal range, 108.7–242.2 nmol/ml); arginine, 40.5 nmol/ml (normal range, 53.6–133.6 nmol/ml); and alanine, 772.6 nmol/ml (normal range, 208.7–522.7 nmol/ml). A high level of urinary orotic acid was also observed in the urine sample collected on day 3.

He developed multiple organ failure and died on day 16 despite use of all available treatments.

**Methods**

Informed consent for genetic analysis was obtained from the patient’s parents, and this study was approved by the ethical committee of the University of Tsukuba, Japan.

PCR analysis using a sample of the patient’s DNA failed to amplify the exons of OTC; this suggests a large deletion in the OTC locus. Next, we performed a high-density SNP assay using Human610-Quad (Illumina, San Diego, CA, USA) that contained more than 610,000 rationally selected tag SNPs and markers per sample, according the manufacturer’s protocol. The scanned image was imported into BeadStudio (Illumina) for analysis. After identifying the deleted region, we designed primers (DelF, 5’-CCCAAGCTTGACTTCTCTGG-3’; DelR, 5’-AGTTCCTGCAGAGCATGAGA-3’) using the Primer 3 software (http://primer3.sourceforge.net/) in order to detect the breakpoints. Subsequently, the PCR product was subjected to direct sequencing using BigDye Terminator v.1.1 Cycle Sequencing Kit (Applied Biosystems, Foster City, CA, USA) on an ABI PRISM 3100 Genetic Analyzer (Applied Biosystems). For carrier testing, a high-density SNP assay and PCR analysis were performed using a DNA sample obtained from the patient’s mother, who had not shown any OTC deficiency-related symptoms.
Results and Discussion

The results of the high-density SNP assay are shown in Fig. 1. We detected a deletion on Xp11.4 (fragment size, approximately 1 Mb). The deleted region includes genes encoding transmembrane 4 superfamily member 2 (TSPAN7), MID1 interacting protein 1 (MID1IP1) and part of RPGR, in addition to OTC. Analysis of breakpoints using PCR and sequencing revealed a telomeric breakpoint in intron 6 of RPGR. The results of the high-density SNP assay and PCR confirmed that the patient’s mother was a carrier of the mutation (Figs. 1, 2).

The clinical picture of OTC deficiency depends on the degree of enzyme activity impairment. Complete deletion of OTC leads to the absence of OTC enzymatic activity in the patient’s liver and this explains why the patient died in the present case. Approximately 20% of female carriers become symptomatic; they have hyperammonemic episodes and exhibit central nervous system damage (9). The patient’s mother, a carrier of the mutation, had not displayed any OTC deficiency-related symptoms or dietary preferences such as avoidance of high-protein foods. In females, X inactivation in the liver is much more skewed and correlates well with the OTC activity, and the degree of X inactivation varies considerably, even within the same liver (9, 10). Although the female carrier
is asymptomatic, she should be alerted to the possibility of developing a hyperammonemic crisis (11).

Recent advances in clinical management of OTC deficiency, including liver transplantation, have improved patient prognosis; therefore, detailed genetic analysis is needed for better management of patients. Most mutations causing OTC deficiency consist of single-base substitutions, while a smaller proportion of mutations consist of small deletions or insertions and larger deletions (2). Several studies have reported a large deletion in OTC a neighboring gene (12, 13), and the results of a recent study involving array CGH revealed partial or complete deletion of OTC in 11 of 70 samples of patients lacking point mutations (6). Previously, breakpoint determination for large unknown deletions was timeconsuming and laborintensive. However, recent DNA chip technology such as array CGH and high-density SNP assays allows us to detect deleted regions within a few days. In this case, the patient lacked the entire TSPAN7 and MID1IP1 genes and part of RPGR in addition to OTC. It has been reported that RPGR is the cause of X-linked retinitis pigmentosa (RP) (8). RP is characterized by night blindness; concentric constriction of visual fields; pigment deposits,
predominantly in the midperiphery of the retina; and attenuation of retinal vessels. In males, X-linked RP is associated with a severe phenotype in terms of the onset and progression of the disease. Females with disease-causing mutations can develop RP; therefore, the patient’s mother was recommended to consult an ophthalmologist for a checkup, although she did not suffer from visual impairment. It has been suggested that TSPAN7 is associated with X-linked mental retardation (14) and autism spectrum disorder (15). The function of MID1IP1 has not yet been elucidated. Analysis of deletion breakpoints did not show the shared breakpoints identified in previous reports (2, 6, 16, 17), suggesting that the deletion is family-specific.

This case has shown that detailed molecular genetic analysis is necessary for patient management and for providing genetic counseling to the family members involved. Use of the widely available high-density SNP array allows for rapid identification of deletion breakpoints; therefore, it will become a standard technique in study of patients with large genomic deletions of contiguous genes for provision of comprehensive genetic counseling and initiation of clinical management.

References

1. Lindgren V, de Martinville B, Horwich AL, Rosenberg LE, Francke U. Human ornithine transcarbamylase locus mapped to band Xp21.1 near the Duchenne muscular dystrophy locus. Science 1984;226:698–700.
2. Yamaguchi S, Brailey LL, Morizono H, Bale AE, Tuchman M. Mutations and polymorphisms in the human ornithine transcarbamylase (OTC) gene. Hum Mutat 2006;27:626–32.
3. Michalak A, Butterworth RF. Ornithine transcarbamylase deficiency: pathogenesis of the cerebral disorder and new prospects for therapy. Metab Brain Dis 1997;12:171–82.
4. Pelet A, Rotig A, Bonaiti-Pellie C, Rabier D, Cormier V, Toumas E, et al. Carrier detection in a partially dominant X-linked disease: ornithine transcarbamylase deficiency. Hum Genet 1990;84:167–71.
5. Batshaw ML, Msall M, Beaudet AL, Trojak J. Risk of serious illness in heterozygotes for ornithine transcarbamylase deficiency. J Pediatr 1986;108:236–41.
6. Shchelochkov OA, Li FY, Geraghty MT, Gallagher RC, Van Hove JJL, Lichter-Konecki U, et al. High-frequency detection of deletions and variable rearrangements at the ornithine transcarbamylase (OTC) locus by oligonucleotide array CGH. Mol Genet Metab 2009;96:97–105.
7. Greenberg CR, Hamerton JL, Nigli M, Wrogemann K. DNA studies in a family with Duchenne muscular dystrophy and a deletion at Xp21. Am J Hum Genet 1987;41:128–37.
8. Meindl A, Dry K, Herrmann K, Manson F, Ciccodicola A, Edgar A, et al. A gene (RPG) with homology to the RCC1 guanine nucleotide exchange factor is mutated in X-linked retinitis pigmentosa (RP3). Nat Genet 1996;13:35–42.
9. Yorifuji T, Muroi J, Uematsu A, Tanaka K, Kiwaki K, Endo F, et al. X-inactivation pattern in the liver of a manifesting female with ornithine transcarbamylase (OTC) deficiency. Clin Genet 1998;54:349–53.
10. Rozen R, Fox JE, Hack AM, Fenton WA, Horwich AL, Rosenberg LE. DNA analysis for ornithine transcarbamylase deficiency. J Inherit Metab Dis 1986;9 (Suppl 1):49–57.
11. Numata S, Harada E, Maeno Y, Ueki I, Watanabe Y, Fujii C, et al. Paternal transmission and slow elimination of mutant alleles associated with late-onset ornithine transcarbamylase deficiency in male patients. J Hum Genet 2008;53:10–7.
12. Quental R, Azevedo L, Rubio V, Diogo L, Amorim A. Molecular mechanisms underlying large genomic deletions in ornithine transcarbamylase (OTC) gene. Clin Genet 2009;75:457–64.
13. Tuchman M, Morizono H, Rajagopal BS, Plante RJ, Allewell NM. The biochemical and molecular spectrum of ornithine transcarbamylase deficiency. J Inherit Metab Dis 1998;21 (Suppl 1):40–58.
14. Abidi FE, Holinski-Feder E, Rittinger O, Kooy F, Lubs HA, Stevenson RE, et al. A novel 2 bp deletion in the TM4SF2 gene is associated with MRX58. J Med Genet 2002;39:430–3.
15. Noor A, Gianakopoulos PJ, Fernandez B, Marshall CR, Szatmari P, Roberts W, et al. Copy number variation analysis and sequencing of the X-linked mental retardation gene TSPAN7/TM4SF2 in patients with autism spectrum disorder. Psychiatr Genet 2009;19:154–5.

16. Arranz JA, Madrigal I, Riudor E, Armengol L, Mila M. Complete deletion of ornithine transcarbamylase gene confirmed by CGH array of X chromosome. J Inherit Metab Dis 2007;30:813.

17. Deardorff MA, Gaddipati H, Kaplan P, Sanchez-Lara PA, Sondheimer N, Spinner NB, et al. Complex management of a patient with a contiguous Xp11.4 gene deletion involving ornithine transcarbamylase: a role for detailed molecular analysis in complex presentations of classical diseases. Mol Genet Metab 2008;94:498–502.